Introduction Age-related macular degeneration (AMD) is a late-onset, chronic eye disease that affects the central retina and is a leading cause of blindness in elderly patients.1 The global estimated prevalence of AMD is 8.69% of the population.2 Neovascular AMD, in particular, is present in 10–15% of all AMD cases and can quickly progress to blindness if left untreated.3 The identification of vascular endothelial growth factor (VEGF) in 1989 presented the opportunity for targeted therapy of...